RBC Capital raised the firm’s price target on Wave Life Sciences (WVE) to $15 from $7 and keeps a Sector Perform rating on the shares. The company’s recent execution has been impressive given its proof of concept for Duchenne Muscular Dystrophy, or DMD, and data last week suggesting that RNA editing could be the next wave of innovation in genetic medicine, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Biotech Alert: Searches spiking for these stocks today
- Korro Bio price target raised to $115 from $100 at H.C. Wainwright
- Wave Life Sciences price target raised to $22 from $11 at Wells Fargo
- Wave Life Sciences price target raised to $17 from $13 at JPMorgan
- Wave Life Sciences price target raised to $20 from $16 at JonesResearch